There is increasing interest in the determination of serum apolipoproteins (apo) A-I and B, because of the evidence indicating that they may be more useful laboratory indices of coronary heart disease than quantification of serum lipids. The lack of standardized methods, common reference ranges and clinical decision values are delaying the widespread use of apo A-I and B measurements. The possibility of obtaining accurate and comparable apo A-I and B values and reference limits has been enhanced by the development of reference materials for these apclipoproteins.l? In previous work, we devised a turbidimetric method for apo A-I and apo B with a Cobas Bio analyser and calculated reference intervals in a sample of 494 apparently healthy subjects.' In this study we have converted these intervals into values that may be obtained using three commercial methods for apo A-I and B which are calibrated against the International Federation of Clinical Chemistry-World Health Organization (I FCC-WHO) reference standards for apolipoproteins.
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MATERIALS AND METHODS

Patient samples
Specimens (220) were collected over a period of 10 days from samples sent to the laboratory for routine analysis. These samples had apo A-I and B concentrations below (44 samples), above (44) or evenly distributed throughout the laboratory reference range (132). Haemolysed, icteric or turbid samples were excluded. Measurements of apo A-I and B of the serum samples were performed on the same day they were drawn, in 10 runs on different days by the four methods, Correspondence: Josefina Eugui. and the instruments were calibrated before each run.
Methods
In-house method A turbidimetric procedure developed for the Cobas Bio analyser,' using reagents obtained from Boehringer Mannheim SA (Barcelona, Spain). The standards had assigned values based on Centers for Disease Control (CDC) reference materials. Briefly, 5 ilL (for apo A-I) or 30 ilL (for apo B) of 51-fold pre-diluted serum was mixed with 200 ilL of the respective antibody (30-fold diluted for apo A-I, 40-fold for apo B). The assays were conducted at 30°C, and absorbance changes (290 nm) were measured between O' 5 sand 15 min for apo A-I, and between O' 5 sand 5 min for apo B. Sample concentrations were calculated using the four-parameter logistic model. The interday coefficients of variation (CV) for this method (n = 10) were 6·0% for apo A-I at 1·37 giL and 5·0% for apo B at 0·69 g/L, Our reference limits were established with this procedure in a sample of 246 women and 248 men, ages 20--83 years.'
The other three methods employed standards which had been calibrated by the manufacturers using the IFCC-WHO reference preparations SPI and SP3. In all the assays, the fourparameter logistic model was used, and the reaction temperature was 37°C. In brief, the assay conditions for these methods were as follows:
BN Jl nephelometer (Behring Diagnosticos Iberica SA, Barcelona, Spain) Ten microlitres of a 20-fold automatically prediluted sample for apo A-I, or 30 ilL for apo B with 160 ilL (apo A-I) or 150 ilL (apo B) of buffer reagent, plus 40 ilL of the respective antibody reagent and 10 ilL of supplementary reagent (Thesit, 50 g/L), Readings at 840 nm were taken at lOs and 6min. Interday (n = 10) Statistics Correlation between the methods was assessed by Passing-Bablok linear regression, and comparison between the measurements was evaluated by the method of Bland and Altman." Analysis of variance was used to test whether the mean values of the apolipoproteins differed among the assays.
RESULTS AND DISCUSSION
Cobas Mira (Roche Diagnostic Systems, Madrid, Spain)
Six microlitres of a 21-fold automatically prediluted sample for apo A-I, or 20 ilL for apo B, were mixed with 160 pL of the respective antibody reagent. Readings at 340 nm were taken at 25 sand 6·7 min. Interday (n = 10) CVs were 4·7% for apo A-I at 1·58 giL and 2·0% for apo B at 0·95 giL.
CVs were 6-4% and 5·7% for apo A-I (1.59 g/L) and apo B (1,05 g/L), respectively.
Using the Bland and Altman approach the differences between the three commercial methods can be seen in Figure I . The comparisons between all four methods of analysis of apo A-I and apo B are shown in Table I . As would be expected, the greatest agreements were found with the three commercial methods, which all used the same reference material (IFFC-based) to calibrate the assays, as opposed to the in-house assay (CDCbased). For apo A-I, the best correlation was between the assays performed on the BNII nephelometer and the Cobas Mira. Considering the imprecision of these methods under routine conditions, the mean difference of 0·017 g/L between these two methods would not be clinically significant. For apo B the comparison was reasonable between all three commercial methods. These differences were within the analytical variation expected for these assays.
The converted reference limits, calculated by using the Passing-Bablok regression equation, are summarized in Table 2 . They are a little higher than those found by Steinmetz et al? with a BNA nephelometer (an earlier Behring analyser), with standards calibrated against the SPI and SP3 reference materials, in a French population. The dissimilarities may be attributed to different diets, lifestyles and genetic factors. corresponding percentiles in the systems we have studied. Only their apo A-I values were slightly lower, and their 90th apo B percentile for women, higher. In our study, BNII and Cobas Mira results can be treated as comparable. More work in this field will probably confirm that the use of IFCC-WHO reference materials will significantly reduce the variability of apo A-I and B measurements made by different methods. The next step will be the establishment of cutoff values analogous to the National Cholesterol Education Program risk levels for cholesterol and its fractions.
